Menu
← Oncology Approval Tracker
FDA DECISION ·
Rybrevant Faspro
amivantamab + hyaluronidase-lpuj · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous treatment for adults across the NSCLC indications approved for intravenous amivantamab, with the regimen determined by EGFR alteration, prior therapy, and treatment setting.
LAMPGEN ANALYSIS
Why it matters
The alternate route showed comparable drug exposure with fewer systemic administration reactions than IV amivantamab in the studied combination.
What research teams should watch
Use the route-specific schedule, review indication-specific companion therapy, and preserve reaction monitoring when changing administration.
PRIMARY RECORDS